Active	Status	Sponsor type	Region	Phase	Filter
6 Active 29 Inactive 35 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Lewis, David A
BRUIN-MCL-321, NCT04662255: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)	Active, not recruiting	3	500	Europe, Canada, Japan, US, RoW	Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa	Loxo Oncology, Inc., Eli Lilly and Company	Lymphoma, Mantle-Cell	12/25	07/26
RITZ, NCT05735834: Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients	Recruiting	3	120	Europe	Rituximab, Truxima, Zanubrutinib, Brukinsa	International Extranodal Lymphoma Study Group (IELSG)	Splenic Marginal Zone Lymphoma	05/29	05/29
RAINBOW, NCT04061512: Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia	Recruiting	2/3	148	Europe	Dexamethasone, cyclophosphamide, rituximab, Rituximab, ibrutinib	University College, London, Janssen-Cilag Ltd.	Waldenstrom Macroglobulinemia	03/30	03/30
EPCORE DLBCL-3, NCT05660967: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma	Recruiting	2	180	Europe, Japan, US, RoW	Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid®	Genmab, AbbVie	Diffuse Large B-Cell Lymphoma	01/26	03/27
OASIS-II, NCT04802590: Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma	Recruiting	2	194	Europe	Ibrutinib 560 mg, Venetoclax 10 MG Oral Tablet [Venclexta], Venetoclax 50 MG Oral Tablet [Venclexta], Venetoclax 100 MG Oral Tablet [Venclexta]	The Lymphoma Academic Research Organisation, Institute of Cancer Research, United Kingdom	Mantle Cell Lymphoma	03/26	09/31
NCT05463263: A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas	Recruiting	1/2	180	Europe, US	STP938	Step Pharma, SAS	Lymphoma, B-Cell, Lymphoma, T-Cell	12/25	12/25
Thierry-Carstensen, Birgit
No trials found